Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's disease.

While therapeutic drug monitoring should be performed at trough, a drug level ≥4.9 μg/mL obtained during the first 9 days predicts a therapeutic trough drug level with reasonable confidence.